Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GH Research PLC - Ordinary Shares (NQ:GHRS)

10.50 -0.26 (-2.42%)
Streaming Delayed Price Updated: 3:56 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GH Research PLC - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
GH Research Reports Full Year 2024 Financial Results and Provides Business Updates
From GH Research PLC
Via GlobeNewswire
These 5 Health Care Stocks Saw The Sharpest Retail Interest Jump Last Week
These five small-cap pharma and biotech stocks drew heavy attention on Stocktwits last week, driven by key trial results, FDA updates, and promising drug developments. 
Via Stocktwits
Exposures Product Safety
On Thursday, there are stocks with unusual volume. Let's take a look.
Let's explore the current happenings on the US markets on Thursday. Below, you'll find the stocks exhibiting unusual volume in today's session. 
Via Chartmill
These stocks have an unusual volume in today's session
Discover the stocks with unexpected trading volume in today's session on the US markets. 
Via Chartmill
GH Research Announces Pricing of $150 Million Public Offering
From GH Research PLC
Via GlobeNewswire
Unusual volume stocks in Tuesday's session
In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look. 
Via Chartmill
GH Research Announces Proposed Public Offering
From GH Research PLC
Via GlobeNewswire
Crude Oil Moves Higher; Owens & Minor Shares Plummet
Via Benzinga
Exposures Fossil Fuels
Dow Falls 150 Points; ISM Manufacturing PMI Rises In January
Via Benzinga
Topics Stocks
Exposures US Equities
IDEXX Laboratories Posts Upbeat Results, Joins Stratasys, Saia And Other Big Stocks Moving Higher On Monday
Via Benzinga
Why Is GH Research Stock Trading Higher On Monday?
GH Research's Phase 2b trial of GH001 for treatment-resistant depression met its primary endpoint, showing significant efficacy and a favorable safety profile. 
Via Benzinga
S&P 500 Down Over 1%; Tyson Foods Posts Upbeat Results
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction
From GH Research PLC
Via GlobeNewswire
Why Triumph Group Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket
Via Benzinga
GH Research to Provide Update on Phase 2b Trial with GH001 in TRD
From GH Research PLC
Via GlobeNewswire
Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents
From GH Research PLC
Via GlobeNewswire
GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates
From GH Research PLC
Via GlobeNewswire
3 Fast-Growing Stocks Analysts See Doubling in Price
Clinical-stage biotech firms often have massive upside potential, but much of that possible success hinges on successful trials and product launches. 
Via MarketBeat
Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week
The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come. 
Via Talk Markets
Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th
While the psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come, the stocks of the companies involved are... 
Via Talk Markets
Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August
The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come and, to monitor their progress we present a... 
Via Talk Markets
Irish Biotech Firm GH Research Sees Cash Decline in Q2, Advances Psychedelic Drug Trials
Irish psychedelic biotech firm GH Research PLC (NASDAQ: GHRS) reported on Tuesday financial results for the second quarter ended June 30, 2024. Cash, cash equivalents, other financial assets and... 
Via Benzinga
GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates
From GH Research PLC
Via GlobeNewswire
GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer
From GH Research PLC
Via GlobeNewswire
Largest Psychedelic Compound -Based Clinical-Stage Drug Stocks Up 6% Last Week
Opportunities to invest in psychedelic stocks are emerging for those willing to get in early, and the 4 largest psychedelic compound-based portfolio drug discovery companies are up 5.9% in the past... 
Via Talk Markets
Psychedelic Compound-Based Drug Stocks Portfolio: Up 17.5% In July; Down 19% MTD
This article highlights the 4 largest market cap clinical-stage psychedelic compound-based drug discovery companies with their stock performances MTD, in July, their areas of focus, and their latest... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.